Clinical Trials Logo

CTCL clinical trials

View clinical trials related to CTCL.

Filter by:
  • None
  • Page 1

NCT ID: NCT05879458 Recruiting - Mycosis Fungoides Clinical Trials

Ritlecitinib in CTCL

Start date: May 17, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to evaluate the effectiveness and safety of Ritlecitinib in skin and blood in persons with Cutaneous T-Cell Lymphoma (CTCL). CTCL is a rare type of cancer that starts in the white blood cells and eventually can result in rashes or tumors in the skin. This study includes a 24 week Treatment Period and a 24 week Follow-up Period. This study will involve physical examinations, visual assessments, laboratory tests, PET-CT scans, electrocardiograms, photographs of your skin, skin biopsies, and hearing tests.

NCT ID: NCT04171791 Completed - CTCL Clinical Trials

A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)

Start date: January 15, 2020
Phase: Phase 1
Study type: Interventional

The objective of this study are to evaluate the safety and tolerability of ABT-199 (venetoclax) in patients with advanced Cutaneous T cell lymphoma (CTCL). A secondary objective is to explore clinical response to ABT-199 (venetoclax) in patients with advanced CTCL.

NCT ID: NCT04087629 Recruiting - CTCL Clinical Trials

StrataCTX® as a Steroid Sparing Device

Start date: July 7, 2021
Phase: N/A
Study type: Interventional

The purpose is to determine if StrataCTX® can be used as a steroid sparing agent for the treatment of cutaneous reactions related to, cutaneous T Cell lymphoma (CTCL) and chemotherapy/immunotherapy treatments than the current standard treatment - topical steroids - in people who are receiving treatment for CTCL, or chemotherapy/immunotherapy for solid/hematologic malignancies. Subjects will have CTCL and are being treated with topical steroids, or being treated with chemotherapy/immunotherapy for another condition and have had cutaneous reactions that have warranted initiation of topical steroids.

NCT ID: NCT03240211 Recruiting - PTCL Clinical Trials

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

Start date: February 2, 2022
Phase: Phase 1
Study type: Interventional

This is an international, multicenter, multi-arm, phase Ib, model-based dose-escalation study. The primary objectives of the study in each arm is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose limiting toxicities (DLTs) and to evaluate the clinical efficacy at the MTD of various combinations of pembrolizumab, pralatrexate and decitabine.

NCT ID: NCT03239392 Completed - CTCL Clinical Trials

A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL

Start date: April 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study is an open-label, multi-center, dose-ranging study to characterize the safety, tolerability, preliminary efficacy, and PK/PD of up to four dose levels of BNZ-1 administered weekly by IV infusion to adults diagnosed with Large Granular Lymphocyte (LGL) Leukemia or refractory Cutaneous T-cell Lymphoma (CTCL).

NCT ID: NCT02757248 Withdrawn - PTCL Clinical Trials

Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL

Start date: November 2016
Phase: Phase 1
Study type: Interventional

This is a phase I study of the combination of volasertib and romidepsin in patients with relapsed/refractory peripheral T cell lymphoma (PTCL) or stage IIB-IV cutaneous T cell lymphoma (CTCL). This study will determine the maximum tolerated dose (MTD) of this combination by treating cohorts of patients at a certain dose combination. The investigators will use a Bayesian design to determine the dose combination for the next cohort of patients and to determine the MTD. Overall response rate as well as adverse events will be monitored and reported.

NCT ID: NCT02556463 Terminated - Cancer Clinical Trials

A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors

Start date: November 4, 2015
Phase: Phase 1
Study type: Interventional

To evaluate MEDI9197 when administered by intratumoral injection to subjects with solid tumors and in combination with durvalumab in subjects with solid tumors.